Pascal Deschatelets - 20 May 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship
Chief Scientific Officer
Issuer ticker
APLS
Reported as of
20 May 2024
Net transaction value
+$92,120
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
21 May 2024, 16:03:03 UTC
Prior SEC filing
09 May 2024
Next SEC filing
14 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 21 May 2024.

Key facts

  • This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 21 May 2024, 16:03.

Change

  • Previous filing in this sequence was filed on 09 May 2024.
  • Current net transaction value: +$92,120.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Options Exercise

Transaction value
$92,120
Shares
+24,500
Change %
+2.2%
Price
$3.76*
Shares after
1,140,483
Date
20 May 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-24,500
Change %
-66%
Price
$0.000000
Shares after
12,780
Date
20 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
24,500
Exercise price
$3.76
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option was granted on 02/08/2016 and is fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .